Business Context and Reporting Period
Company: NewAmsterdam Pharma Company N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: October 18, 2024
Reporting Period: The filing addresses errors in historical financial statements for the years ended December 31, 2021, and 2022, as well as the three-year period ended December 31, 2022.
Key Financial Metrics
This filing does not report current revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on a restatement of historical Net Loss Per Ordinary Share (EPS) due to calculation errors.
Material Changes Versus Prior Period
The Audit Committee concluded that previously issued consolidated financial statements (the "Affected Financial Statements") should no longer be relied upon. The material change involves a correction of errors in the calculation of net loss per ordinary share for the periods ending December 31, 2021, and 2022. The error occurred because the number of ordinary shares outstanding at the end of each period was erroneously reported as the weighted average number of ordinary shares outstanding.
Guidance, Outlook, and Management Commentary
- Management Action: The Audit Committee, in consultation with management and the independent registered public accounting firm (Deloitte Accountants B.V.), identified the misstatement.
- Scope of Error: The erroneous calculations were not included in the financial statements for the year ended December 31, 2023, or the three-year period ended December 31, 2023, which were prepared under U.S. GAAP.
- Next Steps: The Company intends to restate the Affected Financial Statements in an amendment to the 2022 Annual Report (Form 20-F) to be filed with the SEC as soon as practicable.
- Risks: The primary risk identified is the unreliability of previously reported EPS figures for the 2021 and 2022 periods.
Important Facts for Investor Verification
- Verify the upcoming amendment to the 2022 Annual Report (Form 20-F) for the corrected Net Loss Per Ordinary Share figures.
- Confirm that the 2023 financial statements (Form 10-K) are unaffected by this specific calculation error.
- Monitor the timeline for the filing of the restatement to assess the speed of remediation.
- Note that the filing does not provide updated operational metrics or current period financial results.